

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
31 July 2003 (31.07.2003)


PCT

(10) International Publication Number
WO 03/062198 A2

- (51) International Patent Classification⁷: **C07D**
- (21) International Application Number: PCT/US03/02380
- (22) International Filing Date: 24 January 2003 (24.01.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/351,390 24 January 2002 (24.01.2002) US
- (71) Applicants: **BARNES JEWISH HOSPITAL** [US/US];
600 S. Taylor, St. Louis, MO 63110 (US). **BRISTOL-MY-
ERS SQUIBB MEDICAL IMAGING, INC.** [US/US];
331 Treble Road, North Billerica, MA 01862 (US).
- (72) Inventors: **LANZA, Gregory,**; 12042 Gardengate Drive,
St. Louis, MO 63146 (US). **WICKLINE, Samuel, A.;**
11211 Pointe Cout, St. Louis, MO 63110 (US). **HARRIS,
Tom;** 56 Zion Hill Road, Salem, CT 06420 (US).
- (74) Agents: **MURASHIGE, Kate, H.** et al.; Morrison & Foer-
ster LLP, 3811 Valley Centre Drive, Suite 500, San Diego,
CA 92130-2332 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,
VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: INTEGRIN TARGETED IMAGING AGENTS



(57) Abstract: Emulsions preferably of nanoparticles formed from high boiling liquid perfluorochemical substances, said particles coated with a lipid/surfactant coating are made specific to regions of activated endothelial cells by coupling said nanoparticles to a ligand specific for QvP3 integrin, other than an antibody. The nanoparticles may further include biologically active agents, radionuclides, or other imaging agents.

WO 03/062198 A2



Published:

— *without international search report and to be republished
upon receipt of that report*

(48) Date of publication of this corrected version:

6 November 2003

(15) Information about Correction:

see PCT Gazette No. 45/2003 of 6 November 2003, Sec-
tion II

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*